Nuvalent, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 10, 2022 at 06:30 am EDT
Share
Nuvalent, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 18.47 million compared to USD 9.84 million a year ago. Basic loss per share from continuing operations was USD 0.38 compared to USD 3.17 a year ago. Diluted loss per share from continuing operations was USD 0.38 compared to USD 3.17 a year ago.
For the six months, net loss was USD 36.02 million compared to USD 16.62 million a year ago. Basic loss per share from continuing operations was USD 0.75 compared to USD 5.37 a year ago. Diluted loss per share from continuing operations was USD 0.75 compared to USD 5.37 a year ago.
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.